Business
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
Alireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\nAlireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients treated with Low Dose IL-2 (LD IL-2) over a 4 month period that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE) and no cognitive decline as observed by the AD Assessment Scale–Cognitive Subscale (ADAS-Cog), and the Clinical Dementia Rating-Sum of Boxes scale (CDR-SB);\n\n\n\nIt has been recently announced here that a double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluating safety and tolerability, biological activity, relevant biomarkers, neuroimaging, and efficacy of LD IL-2 in 38 patients with mild-to-moderate AD over 30 weeks is fully enrolled and will release top line data in the first half of 2024;\n\n\n\nCoya’s proprietary investigational LD IL-2 (COYA 301) for subcutaneous administration has been designed to enhance the function of Tregs in vivo and is being developed as a monotherapy for the treatment of AD.\n\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced that Dr. Alireza Faridar, Assistant Professor of Neurology at Houston Methodist and Weill Cornell Medical College, will give an oral presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Disease held in Lisbon, Portugal between March 5-9, 2024. Details and Registration for the conference are found here.\n\n\nDr. Faridar and team are currently conducting a double-blind, randomized, well-controlled study in 38 AD patients evaluating the safety and tolerability, biological activity, blood and cerebrospinal fluid biomarkers, neuroimaging, and changes in cognitive function of LD IL-2 compared to placebo at pre-specified timepoints over the course of a 21-week treatment period and at 9 weeks after the last dose of study treatment.\n\n\nTopline results of this study are anticipated to be reported in the first half of 2024. The study is funded by the Gates Foundation and the Alzheimer’s Association.\n\n\nAbout Alzheimer’s Disease\n\n\nAl...